The KRAS mutation is usually linked to microsatellite-instability (MSI) EC and has been linked to type I EC (10–30%) [189,190]: The Tumor Cancer Genome Atlas (TCGA) investigation of EC patients reported that KRAS-mutated ECs have a greater and more significant estrogen signaling activation due to enhanced RAS/MAPK pathway signaling. The gene discussed is KRAS; the disease is neoplasm.